Skip to main content
Year archive

Ascentage Pharma Group International — 2022 filings

All 60 regulatory filings released by Ascentage Pharma Group International (6855) in 2022, sourced directly from the official regulator.

60 Filings
2022 Period
2022 filings (60)
Filing Released Lang
Terms of Reference for Remuneration Committee
Remuneration Information
2022-12-30 English
VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA DELIVERS ORAL REPORT AT THE 2022 AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING ON THE LATEST DATA RESULTS OF APG-2575 IN COMBINATION WITH BTKI IN PATIEN
Regulatory Filings
2022-12-13 English
VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA DELIVERS ORAL REPORT ON THE CHINESE AND US STUDIES OF OLVEREMBATINIB (HQP1351) AT 2022 ASH ANNUAL MEETING
Regulatory Filings
2022-12-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2022
Share Issue/Capital Change
2022-12-05 English
VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA'S GLOBAL INDUSTRIAL BASE HAS OBTAINED A PRODUCTION LICENSE
Regulatory Filings
2022-11-27 English
VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA ANNOUNCES IND APPROVAL IN CHINA FOR PHASE I STUDY OF APG-5918 IN PATIENTS WITH ADVANCED SOLID TUMORS OR HEMATOLOGIC MALIGNANCIES
Regulatory Filings
2022-11-10 English
VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA RELEASES PHASE I RESULTS OF IAP ANTAGONIST APG-1387 IN AN ORAL REPORT AT THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES ANNUAL MEETING SHOWING POTEN
Regulatory Filings
2022-11-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2022
Regulatory Filings
2022-11-04 English
VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA IS TO PRESENT FIVE STUDIES OF OLVEREMBATINIB, APG-2575, AND APG-115 AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING, FOUR OF WHICH HAVE BEEN SELECT
Investor Presentation
2022-11-03 English
CHANGE OF COMPANY EMAIL ADDRESS
Regulatory Filings
2022-11-01 English
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME
Transaction in Own Shares
2022-10-31 English
VOLUNTARY ANNOUNCEMENT - ACQUISITION OF SHARES BY THE CHAIRMAN AND EXECUTIVE DIRECTOR
Director's Dealing
2022-10-30 English
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME
Transaction in Own Shares
2022-10-28 English
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME
Transaction in Own Shares
2022-10-27 English
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME
Transaction in Own Shares
2022-10-26 English
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME
Transaction in Own Shares
2022-10-25 English
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME
Transaction in Own Shares
2022-10-21 English
Voluntary Announcement - Ascentage Pharma to Announce Results from Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting
Regulatory Filings
2022-10-20 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2022
Regulatory Filings
2022-10-07 English
INTERIM REPORT 2022
Interim / Quarterly Report H1 2022
2022-09-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2022
Regulatory Filings
2022-09-06 English
ANNOUNCEMENT OF UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2022
Interim / Quarterly Report H1 2022
2022-08-26 English
NOTICE OF BOARD MEETING
Report Publication Announcement
2022-08-16 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2022
Regulatory Filings
2022-08-03 English
CLARIFICATION ANNOUNCEMENT IN RELATION TO (1) CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG AND (2) CHANGE OF ADDRESS OF HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE
Regulatory Filings
2022-08-01 English
(1) CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG AND (2) CHANGE OF ADDRESS OF HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE
Regulatory Filings
2022-07-29 English
Voluntary Announcement - Study of Ascentage Pharma's Olverembatinib Approved in Canada
Regulatory Filings
2022-07-22 English
Voluntary Announcement - Ascentage Pharma Announces that the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistan
Regulatory Filings
2022-07-19 English
SUPPLEMENTAL ANNOUNCEMENT - (1) ADOPTION OF THE 2022 RSU SCHEME&#x3b; AND (2) INITIAL GRANT OF AWARDS UNDER THE 2022 RSU SCHEME
Capital/Financing Update
2022-07-14 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2022
Share Issue/Capital Change
2022-07-07 English
Voluntary Announcement - Ascentage Pharma's Novel Potent EED Inhibitor APG-5918 Obtained IND Clearance by the US FDA and will launch First-in-Human Study
Regulatory Filings
2022-06-29 English
(1) ADOPTION OF THE 2022 RSU SCHEME&#x3b; AND (2) INITIAL GRANT OF AWARDS UNDER THE 2022 RSU SCHEME
Share Issue/Capital Change
2022-06-23 English
Voluntary Announcement - Ascentage Pharma Releases Encouraging Clinical Results of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients with Relapsed/Refractory Non-Hodgkin Lymphomas
Regulatory Filings
2022-06-13 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2022
Regulatory Filings
2022-06-07 English
NOTIFICATION LETTER
Report Publication Announcement
2022-05-31 English
2021 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Environmental & Social Information
2022-05-31 English
Voluntary Announcement - Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development
Regulatory Filings
2022-05-27 English
Voluntary Announcement - Ascentage Pharma to Present Latest Clinical Data of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas at 2022 European He
Regulatory Filings
2022-05-23 English
List of directors and their roles and functions
Board/Management Information
2022-05-20 English
SECOND AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
Governance Information
2022-05-19 English
(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 19, 2022&#x3b; (2) RESIGNATION OF NON-EXECUTIVE DIRECTORS&#x3b; (3) CHANGE IN COMPOSITION OF THE REMUNERATION COMMITTEE&#x3b; AND (4) AMENDME
Declaration of Voting Results & Voting Rights Announcements
2022-05-19 English
Voluntary Announcement - Ascentage Pharma Announces Preclinical Data Demonstrating Olverembatinib's Therapeutic Potential in Treating COVID-19 Published in EMBO Molecular Medicine
Regulatory Filings
2022-05-18 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2022
Regulatory Filings
2022-05-06 English
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2022
Regulatory Filings
2022-05-06 English
Voluntary Announcement - Ascentage to Present Data from Seven Clinical Studies at ASCO 2022
Regulatory Filings
2022-04-28 English
Voluntary Announcement - Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022
Regulatory Filings
2022-04-14 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2022-04-13 English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 19, 2022
AGM Information
2022-04-13 English
PROPOSED RE-ELECTION OF RETIRING DIRECTORS, PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION AND NOTICE OF
Proxy Solicitation & Information Statement
2022-04-13 English
ANNUAL REPORT 2021
Annual Report FY 2021
2022-04-13 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2022
Regulatory Filings
2022-04-07 English
Voluntary Announcement - Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Rare Pediatric Disease Designation by the US FDA for the Treatment of Neuroblastoma
Regulatory Filings
2022-03-22 English
PROPOSED AMENDMENTS TO THE AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
Governance Information
2022-03-21 English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2021
Annual Report FY 2021
2022-03-21 English
Voluntary Announcement - Ascentage Pharma Announces First Patient Dosed in China in the Pivotal Phase II Study of Bcl-2 Selective Inhibitor Lisaftoclax (APG-2575) for the Treatment of R/R CLL&#x2
Regulatory Filings
2022-03-15 English
NOTICE OF BOARD MEETING
Regulatory Filings
2022-03-09 English
Ascentage Pharma to Present Latest Results from Six Preclinical Studies at American Association for Cancer Research (AACR) Annual Meeting 2022
Regulatory Filings
2022-03-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2022
Regulatory Filings
2022-03-03 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2022
Regulatory Filings
2022-02-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2021
Regulatory Filings
2022-01-06 English